Abstract
Gastric cancer is the second most common cause of cancer-related mortality worldwide. Accurate prediction of disease progression is difficult, and new biomarkers for clinical use are essential. Recently, we reported that the proteasome-associated deubiquitinating enzyme UCHL5/Uch37 is a new prognostic marker in both rectal cancer and pancreatic ductal adenocarcinoma. Here, we have assessed by immunohistochemistry UCHL5 tumor expression in gastric cancer. The study cohort comprised 650 patients, who underwent surgery in Helsinki University Hospital, Finland, between 1983 and 2009. We investigated the association of cytoplasmic UCHL5 tumor expression to assess clinicopathological parameters and patient survival. Positive cytoplasmic UCHL5 tumor immunoexpression is linked to increased survival of patients with small (<5 cm) tumors (p = 0.001), disease stages I-II (p = 0.025), and age 66 years or older (p = 0.037). UCHL5 is thus a potential marker in gastric cancer with new prognostic relevance.
References
Jun 27, 2003·The New England Journal of Medicine·Paul G RichardsonKenneth C Anderson
Dec 29, 2004·Annals of Surgery·Bryan J DickenStewart M Hamilton
Sep 27, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherAndré Goy
Dec 29, 2007·Molecular Biology of the Cell·Elena KoulichGeorge N DeMartino
Mar 9, 2010·Clinical Chemistry·Catharine M SturgeonUNKNOWN National Academy of Clinical Biochemistry
Nov 5, 2010·PloS One·Amin Al-ShamiTamas Oravecz
Nov 8, 2011·Nature Medicine·Pádraig D'ArcyStig Linder
May 23, 2012·Digestive Diseases and Sciences·Yanjie ChenXizhong Shen
Dec 12, 2012·Biochimica Et Biophysica Acta·Ying FangXizhong Shen
Jun 12, 2013·Cell·Carlos López-OtínGuido Kroemer
Jun 19, 2013·Cell Reports·Olli MatilainenCarina I Holmberg
Dec 10, 2013·Blood·Ze TianKenneth C Anderson
Jan 25, 2014·Trends in Cell Biology·Gary Kleiger, Thibault Mayor
Jun 11, 2014·Scientific Reports·Ningning LiuJinbao Liu
Aug 6, 2014·Current Cancer Drug Targets·Q Ping Dou, Jeffrey A Zonder
Aug 16, 2014·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Lin WangRui-Qin Tu
Dec 3, 2014·Pharmacology & Therapeutics·Padraig D'ArcyStig Linder
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Feb 24, 2015·Molecular Cell·Danny D SahtoeTitia K Sixma
Feb 24, 2015·Molecular Cell·Ryan T VanderLindenChristopher P Hill
May 15, 2015·Oncotarget·Rongbin WeiShangfeng Liu
Jul 18, 2015·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Karthik SelvarajuPádraig D'Arcy
Dec 18, 2015·PloS One·Alli LaitinenCaj Haglund
Jun 7, 2016·Scientific Reports·Xin WangPadraig D'Arcy
Jun 28, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Leena ArpalahtiCarina I Holmberg
Jul 7, 2017·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Leena ArpalahtiCarina I Holmberg
Aug 31, 2017·PloS One·Alli LaitinenCaj Haglund
Citations
May 3, 2018·PloS One·UNKNOWN PLOS ONE Staff
Nov 2, 2019·Oncotarget·Shiho FukuiTakuya Ayabe
Jan 4, 2020·Oncology Letters·Jiangang SunYongshun Gao
Jul 31, 2020·International Journal of Molecular Sciences·Ji Yeong ShinByung-Hoon Lee
Jun 6, 2018·Cancer Biomarkers : Section a of Disease Markers·Chen-Guang LiuJian-Sheng Guo
Jul 1, 2020·Frontiers in Oncology·Da LiuLing Ouyang
May 1, 2020·Cellular & Molecular Biology Letters·Zheng ZhangQi Yuan
Aug 23, 2019·Expert Review of Anticancer Therapy·Shunsuke NakamuraYasuhiro Kodera
Nov 5, 2019·Life Sciences·Bing LiuSong Zhang
Feb 16, 2021·Frontiers in Oncology·Chao RongJochen Hess